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Abstract Tinnitus is a subjective perception of phantom sound that currently cannot be objectively measured.
However, there is growing evidence suggesting that the biological source of tinnitus may exist in one or more than
one place in the auditory pathway. Recent studies have found that neurotransmitters or modulators, such as gluta-
mate, γ-aminobutyric acid(GABA), serotonin, dynorphin, dopamine, neurosteroid, acetylcholine(ACh) and sub-
stance P, are involved in tinnitus generation. Animal and human studies have shown that some of these neurotrans-
mitters and the agonists or antagonists of their receptors either affect tinnitus behaviors or demonstrate some de-
gree of treatment effects on tinnitus. However, due to the unclear biological mechanisms of tinnitus and side ef-
fects of these drugs, the value of clinical usage of such drugs in treating tinnitus is yet to be established. Revealing
the relationship between tinnitus and neurotransmitter receptor functions will help identify more effective drugs for
tinnitus treatment. This article reviews the literature of neurophysiological studies on tinnitus in both animal and
human subject studies at various levels of the auditory pathway.
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Introduction
Tinnitus is assessed based on patient’s subjective
description rather than pathological source due to the
lack of knowledge of its mechanisms and available
objective measurement. However, there is growing
evidence suggesting that tinnitus is more than a
psychological hallucination. It has one or more than
one physiologic source in the auditory pathway and/or
in other parts of the central nervous system. Although
it is still not clear where tinnitus is located, e.g., in the
ear or in the brain, in the auditory system or in
non-auditory systems, significant progress has been
made in the past ten years that links tinnitus with
neurological changes in the brain. Since
neurotransmitter release from neuron presynaptic
structures and the response in postsynaptic structures
play an important role in auditory signal generation,
transmission and perception, dysfunction of certain
neurotransmitters and their receptors may be a key in
triggering tinnitus generation. Localizing the origin
and cause of tinnitus using neurophysiological
approach has become a critical issue in finding a
treatment of tinnitus to help millions of patients who
suffer from tinnitus. The goal of this paper is to
summarize recent findings on neurotransmitters and
neurotransmitter receptors related to tinnitus
mechanisms and treatment.
Glutamate Receptor
Glutamate is one of the most important excitatory
neurotransmitters in both peripheral and central ner-
vous systems. In the inner ear, glutamate is released
by hair cells and received by the dendrites of afferent
spiral ganglion neurons through two different types of
neurotransmitter receptors, non-NMDA and NMDA re-
ceptors[1]. These two receptors work as a dual receptor
system. Non-NMDA receptors include the kainic acid
subtype and the AMPA subtype and probably contrib-
ute to the fast response of spiral ganglion neurons.
NMDA receptors are likely involved in a slow effect[2].
A peripheral tinnitus model suggests that a typical pat-
tern of depolarization of the afferent nerve depends on
the balance of the normal synaptic function. Inner ear
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diseases, such as presbycusis, sudden hearing loss and
noise-induced hearing loss, may involve dysfunction of
cochlear-synaptic functions, causing an increase in
spontaneous neuronal activities. Evans found that ad-
ministration of salicylate increased spontaneous dis-
charges of auditory nerves in cats[3, 4]. The increased
spontaneous activity of afferent nerves was suggested
to be a physiological source of tinnitus. Based on this
hypothesis, Ehrenberger et al studied the effect of
caroverine(a calcium channel blocker and antagonist of
AMPA and NMDA receptors) on tinnitus in animal
models[5, 6, 7]. They found that applying caroverine on
the round window exhibited a statistically significant
protective action in noise-induced hearing loss and tin-
nitus. However, Muller et al studied salicylate effects
on auditory nerve activity in gerbils and found that
spontaneous activities in auditory nerves were signifi-
cantly decreased or remained unchanged after salicy-
late injection. They concluded that the salicylate-in-
duced increasing activities in the central auditory sys-
tem were not caused by cochlear nerve hyperactivity[8].
The peripheral tinnitus model therefore cannot fully ex-
plain the causes of tinnitus.
GABA Inhibition
The central tinnitus model is based on the plasticity
change of the central auditory system in response to
peripheral damage. GABA, a major inhibitory
neurotransmitter in the central auditory pathway, plays
an important role in processing acoustic stimuli[9] and
in central reorganization after peripheral damage[10, 11, 12].
Cochlear damage induced by noise exposure or aging
can cause a decrease in glutamic acid decarboxylase
（GAD）expression, an enzyme for GABA synthesize,
in the cochlear nucleus（CN）and the inferior colliculus
（IC）［13, 14, 15］. GABA concentration changes can affect
auditory signal processing including tuning curve,
filtering, masking and amplification in the central
auditory system. Syka reported that acute noise
exposure induced an increase of middle latency
responses recorded from the auditory cortex (AC)
which might be related to damage of the GABA
inhibitory system[16]. Suneje et al found a depressed
GABA release several days after bilateral removal of
the ossicles and elevated GABA release 4 months after
middle ear removal ［12］. Bauer et al studied GAD
expression and binding characteristics of GABA-A
receptors in the auditory brainstem in rats after tinnitus
was induced by salicylate［17］. They found a significant
elevation of GAD levels in the IC in rats showing
tinnitus behavior, presumably to compensate GABA
reduction. They also found that the number of
GABA-A binding sites decreased significantly in rats
with tinnitus. These studies suggest a connection
between decreased inhibitory activity and tinnitus
behavior. Based on the plasticity hypothesis, studies
aimed at increasing GABA inhibition in the central
auditory system to reduce tinnitus have been conducted
in animal models. Administration of baclofen, a
GABA-B receptor agonist, resulted in a blocking effect
on amplitude enhancement in the IC induced by noise
exposure[18]. Vigabatrin, a GABA receptor agonist used
for treating epilepsy, was found to suppress
noise-induced tinnitus in rats［19］. However, in a recent
human subject study, gabapentin, which has a similar
chemical structure as GABA and is also used for
treating epilepsy, failed to show a sufficient effect on
reducing tinnitus[20]. This leads to the assumption that
tinnitus can arise from multiple sources and involve
more than one neurotransmitter such as GABA.
Serotonin (5-HT) Expression
Serotonin is a neurotransmitter broadly expressed
in the central nervous system and affects a wide range
of biological and behavioral functions, such as
emotions, anxiety and stress. As stress and anxiety are
common symptoms in tinnitus patients, the role of
serotonin in persistent distressing tinnitus has been
studied in order to develop an effective
pharmacological intervention to ameliorate tinnitus.
Studies have found that patients who are under stress
normally show a low level of serotonin concentration
in blood samples and that increasing serotonin level by
taking serotonin reuptake inhibitor types of drugs
lessens symptoms in some patients［２１］. Sachanska et
al. tested blood serotonin concentration in patients with
and without tinnitus ［22］. They found that tinnitus
patients showed significantly higher serotonin values
in their blood than those without tinnitus[22]. In animal
studies, Liu et al. found that salicylate(350 mg/kg, i.p.)
induced a dramatic increase of serotonin levels in both
the IC and the AC. They also found exceeding levels of
glucose and lactate, suggesting an increase of neuronal
activity in the brain ［23］. This study implies that
increased serotonin levels induced by salicylate may
relate to neuronal activity changes and tinnitus. This
may explain why some antidepressant drugs, most of
them serotonin reuptake inhibitors, may provoke or
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worsen tinnitus rather than lessen it［24］. The relationship
between tinnitus and stress and the role of serotonin
expression in these conditions need to be clarified.
Dynorphin, Dopamine and Efferent Systems
Inner ear excitation is largely generated by inner
hair cells(IHC) and carried to the central auditory
system by afferent nerves. The afferent neuronal
activity is modulated by the lateral efferent system
through the release of various neurotransmitters, such
as dynor- phins［25, 26］ and dopamines［27, 28］. Dynorphins
are a class of peptides produced by a variety of
neurons and primarily works as an agonist on opioid
receptors. Extreme anxiety or stress can stimulate
widespread release of endogenous dynorphins which in
turn exert an extensive range of physiologic and
behavioral effects ［29, 30］. Excessive amounts of
dynorphins can be released from the lateral efferent
axons into the synaptic region underneath inner hair
cells in the cochlea during intense noise exposure［26, 30］.
The presence of dynorphins can either increase IHC’s
spontaneous release of glutamate or enhance the
response of NMDA receptors to glutamate, which has
been hypothesized to be related with tinnitus
generation. However, in neurons in the trigeminal and
hippocampus nuclei, dynorphins have been shown to
have both enhancement and suppression effect on
NMDA receptors ［31, 32, 33］. The direct effects of
dynorphins on NMDA receptors in the cochlea have
yet to be studied.
Dopamine also shows a modulating effect on IHC
depolarization and on spiral ganglion neuron firing
properties. In human studies, administration of dopa-
mine receptor antagonists, such as sulpiride and melato-
nin, reduces tinnitus perceptions. In a clinical study
which involved 120 patients, tinnitus perception was re-
duced by 56% by administration of sulpiride, 40% by
melatonin administration, and 81% by sulpiride plus
melatonin［34］. However, since there is not objective
measurement of tinnitus, a strong placebo effect has
been found in tinnitus treatment. The efficacy of these
drugs needs to be confirmed. Dopamine receptors are
also expressed in the central auditory system. The ef-
fects of dopamine antagonist on central system should
be also evaluated［35］.
Mineralocorticoid Receptors and Neurosteroid
Neurosteroids, which are synthesized in the cen-
tral nervous system, exert a wide range of effects on
memory, behavior and neuroprotection. Neurosteroids,
such as pregnenolone and dexamethasone, have been
used in clinical treatment of inner ear diseases, such as
sudden sensorineural hearing loss［36, 37］, Meniere’s dis-
ease［38, 39］ as well as tinnitus［40, 41, 42, 43］. However, the ef-
fect of steroid treatment on tinnitus is far from consis-
tent. Sakata conducted a retrospective study on the
transtympanic dexamethasone treatment on tinnitus
and found that application of 2-4 mg dexamethasone
on the round window showed a positive effect on the
patients who had low-pitched tinnitus, but little effect
on those with high pitched tinnitus［43］. Some studies
have suggested that steroid effect in the inner ear is me-
diated by mineralocorticoid receptors since the effect
of neurosteriod can be blocked by spironolactone, a
mineralocorticoid receptor antagonist ［44］. As some
neurosteroid receptors, e.g., glucocorticoid and miner-
alocorticoid receptors, are widely expressed in the in-
ner ear on spiral ganglion neurons, organ of Corti and
spiral limbus［45, 46］, pharmacologic treatments that selec-
tively target mineralocorticoid receptors may prove to
be a better treatment option that can provide clinical
benefits while avoiding side effects from neurosteroid
treatment［44］.
Neurosteroids have also shown a neural
protecting effect in the cochlea in response noise
exposure. After the exposure to loud noise,
administration of mifepristone elevated the compound
action potential amplitude significantly compared to
saline treatment ［47, 48］. The effects of mifepristone
presumably involve blocking cell death following
noise exposure through glucocorticoid receptors
expressed in IHCs and afferent nerve fibers. The neural
pathway of neurosteroids in protecting cell death is
still not clear. One hypothesis is the role played by the
stria vascularis. Steroids affect maintenance of normal
cochlear fluid homeostasis by secreting potassium into
the endolymph. Prednisolone, hydrocortisone or
dexamethasone cause an increase of current density in
isolated stria vascularis in a dose-dependent manner by
increasing the secretion of potassium[49]. This can
conceivably account for some of the physiological and
clinical effects of neurosteroids on inner diseases and
tinnitus.
Cholinergic Receptors and Cochlear Nucleus Activity
Kaltenbach et al reported that intense sound expo-
sure induced an increase in spontaneous activity in the
dorsal cochlear nucleus(DCN) ［50-53］. This evidence has
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been used as an important etiological factor in the CN
for tinnitus generation. Their studies also suggest that
noise exposure-induced hyperactivity in the CN is relat-
ed with the cholinergic modulation change in the DCN
as a result of both changes in cholinergic inputs and
cholinergic receptors[54]. Jin et al reported that the aver-
age choline acetyltransferase activity increased signifi-
cantly in the DCN on the exposed side. Application of
carbachol, a cholinergic agonist, on DCN surface in-
duced a decrease in spontaneous activity in fusiform
cells. The suppression induced by carbachol was con-
siderably stronger in sound exposed animals than the
control animals, suggesting an association between
sound exposure-induced increase in spontaneous activi-
ties and upregulation of cholinergic receptors expres-
sion in the DCN [55].
Cholinergic changes can also affect other part of
the central auditory system, since cholinergic nerves
and their receptors are expressed in the thalamus and
the AC［56］. Cholinergic neuron activities show a broad
effect on auditory physiological and behavioral
responses, such as auditory attention, memory and
learning. Damage of the cholinergic neuron or its
receptors can induce a variety of behavioral deficits
and may be related to tinnitus and other central
auditory processing disorders. In the AC, cholinergic
neurotransmitter receptors are expressed together with
other neurotransmitters including glutamate and
GABA. Excitation of cholinergic neurons shows a
strong modulating effect on glutamate and GABA
release. Thus, damage of cholinergic neurons or their
receptors can affect glutamate and GABA functions.
Recent studies have shown that scopolamine, a
cholinergic receptor antagonist, suppresses
salicylate-induced plasticity change in the AC［57］. In
our pilot studies, scopolamine is also shown to
suppress salicylate-induced tinnitus behavior in rats
(unpublished).
Substance P and Pain Receptors
There are many analogies between phantom pain
and tinnitus. Like tinnitus, pain is a subjective
perception and the amount of pain is difficult to
quantify［58］. Pain can arise from a great variety of
lesions and no specific mechanism for the perception
has been identified. Chronic pain is often a
consequence of a peripheral injury, but the injury itself
may not account for the sustained nature of the chronic
pain. The peripheral damage may induce a persistent
central change even after the acute injury has resolved,
which we often name as a plasticity change in the
central nerve system-although the location, pathology
of this central change are often not known［59］.
Several neurotransmitters and their receptors are
related to pain. One of the important pain-related
peptides is substance P, which is broadly expressed in
the peripheral and central nervous systems. Recent
studies on neurokinin-1 receptor(NK1, substance P
receptor) gene knock- out mice suggested that
substance P has an important and specific role in the
central nociceptive and peripheral inflammatory
responses to noxious stimuli that evoke neurogenic
inflammation ［60］. In the peripheral nervous system,
substance P is involved in the development of
inflammatory pain hypersensitivity in spinal cord
neurons, showing a decreased threshold for action
potential firing and increased responsiveness to a given
stimulus［61, 62］. In the central nervous system, substance
P contributes to seizures, hippocampal excitability, etc
［63, 64］. NK1 antagonists have been tested for therapeutic
targets in different types of pain, including dental pain
(toothache), osteoarthritis, neuropathic pain and
migraine［65］. Since the mechanism involved in pain has
been implicated in tinnitus, substance P and its receptors
may also be involved in tinnitus gener-ation［66］.
Substance P has been identified in a number of
structures in the cochlea and vestibular system,
including hair cells, spiral ganglion cells and
cochlear vessels ［ ６７ － ６９］. Substance P can
modulate cochlear function through neurokinin
receptors. Perilymphatic perfusion of substance P
methyl ester(SPME), a SP receptor agonist, produces a
dose-dependent increase in the amplitude of the
compound action potential, whose effects are blocked
by SP antagonists ［70］. This suggests that SP may
modulate the activity of type I spiral ganglion neurons
through NK1 receptors. Substance P may also play a
role in hyperalgesia and tinnitus. Changes of
substance P agonists and antagonists in spiral ganglion
neural activity can lead to hyperactivity in the auditory
nerve, one of the putative mechanisms of cochlear
tinnitus［4，50］. One pathway of substance P that may be
involved in tinnitus, vertigo, and hearing deficits
associated with basilar artery migraine headaches is
aberrant trigeminal nerve activity ［71］. However, the
mechanism of substance P in tinnitus and other inner
ear diseases is still not clear.
In conclusion, significant progress has been made
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in the past ten to fifteen years regarding tinnitus
mechanism and treatment. Various neurotransmitters
and their receptors have been found to be involved in
tinnitus generation. Such findings provide the hope of
developing effective tinnitus treatment using
pharmacological agents interacting with these
neurotransmitters and their receptors.
Neurophysiologic studies aimed at locating the source
and pathologic mechanisms of tinnitus will be critical
to finding the solution for this common illness.
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